Table 1 Patients’ baseline characteristicsa
From: Effects of ghrelin treatment on exertional dyspnea in COPD: an exploratory analysis
Ghrelin, n = 9 | Placebo, n = 7 | |
|---|---|---|
Age, years | 69.8 (5.9) | 73.6 (4.6) |
Sex, males/females | 9/0 | 6/1 |
Height, cm | 161.8 (6.2) | 160.8 (6.0) |
Weight, Kg | 49.6 (6.3) | 48.1 (8.8) |
BMI, kg/m2 | 18.9 (2.0) | 18.5 (2.5) |
Cigarettes, pack-years | 61.5 (29.9) | 62.8 (20.6) |
Pulmonary function | ||
FEV1, L | 0.81 (0.21) | 0.85 (0.26) |
%FEV1, % predicted | 30.7 (9.1) | 35.1 (11.2) |
FEV1/FVC, % | 41.8 (8.1) | 43.5 (9.1) |
VC, L | 2.54 (0.44) | 2.74 (0.57) |
%VC, % | 79.0 (11.4) | 91.2 (15.5) |
RV, L | 2.80 (0.42) | 3.12 (0.66) |
RV/TLC, % | 52.5 (7.3) | 53.1 (5.4) |
IC, L | 1.51 (0.26) | 1.80 (0.34) |
DLco, % predicted | 61.5 (25.2) | 79.1 (24.5) |
Exercise capacity in ICPET | ||
Peak work rate, Watts | 37.8 (13.0) | 37.1 (7.6) |
Peak \({\dot{V}}_{{\rm O}_{2}}\), mL/kg/min | 13.5 (3.8) | 14.3 (3.2) |
Medications | ||
LAMA | 7 | 3 |
SAMA | 1 | 1 |
LABA | 5 | 3 |
ICS | 3 | 1 |
Methylxanthines | 4 | 3 |